Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Over the last decade, the immune checkpoint blockade targeting the programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free and overall survival of advanced non-small cell lung cancer (NSCLC) patients. PD-L1 tumor expression, along with tumor mutational...

Full description

Bibliographic Details
Main Authors: Vera Kloten, Rita Lampignano, Thomas Krahn, Thomas Schlange
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cells
Subjects:
liquid biopsy
CTCs
immune checkpoint inhibitors
PD-L1 expression
NSCLC
Online Access:https://www.mdpi.com/2073-4409/8/8/809

Internet

https://www.mdpi.com/2073-4409/8/8/809

Similar Items